Search

Displaying results 7161 - 7170 of 10000 in total
  1. Drug

    MIP-1095 I-131

    go.drugbank.com/drugs/DB14978
    Investigational

    MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).

  2. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the

    Synonyms: myristoylated recombinant SCR1-3 of human complement reseptor type I
  3. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).

  4. Drug

    Imazodan

    go.drugbank.com/drugs/DB20144
    Experimental

    Imazodan is a small molecule drug. The usage of the INN stem '-dan' in the name indicates that Imazodan is a cardiac stimulant, pimobendan derivative.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Phenethyl Isothiocyanate

    go.drugbank.com/drugs/DB12695
    Investigational

    Phenethyl Isothiocyanate has been used in trials studying the prevention and treatment of Leukemia, Lung Cancer, Tobacco Use Disorder, and Lymphoproliferative Disorders.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

  7. Drug

    ZEN-012

    go.drugbank.com/drugs/DB06042
    Experimental

    ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. … ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.

  8. Drug

    Staurosporine

    go.drugbank.com/drugs/DB02010
    Experimental

    An indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)

  9. Drug

    Rheinanthrone

    go.drugbank.com/drugs/DB13175
    Experimental

    Rheinanthrone is the active metabolite of senna glycoside [DB11365] known for its laxative effect [A19235]. It is commonly produced by plants of the Rheum species [L772].

  10. Drug

    NGD-4715

    go.drugbank.com/drugs/DB06027
    Experimental

    NGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.